Supira Medical Announces FDA Approval

Supira Medical has announced FDA approval for its SUPPORT II pivotal trial, marking a significant advancement in its work on percutaneous ventricular assist devices (pVADs). The company is focused on transforming the treatment landscape for cardiogenic shock. The appointment of D. Keith Grossman to its Board of Directors further strengthens its leadership team. This news signals progress in developing critical medical technologies aimed at improving patient outcomes in severe cardiac conditions.